Technical analyst Anil Singhvi has maintained 'buy' rating on Aurobindo Pharma Limited stock with an intraday target of Rs 1240.

According to analyst, the investors can purchase the stock with a stop loss of Rs 1154.

The stock of the bank, on February 04, closed at Rs 1175 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1375 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 96.56 and 12.25 respectively.

Aurobindo Pharma Ltd has registered a net profit of Rs 1838.50 million for the three month period ended December 2010 as against Rs 1482.60 million for the same period of 2009.

Company's total Income surged to Rs 11576.60 million for October-December quarter as against Rs 8131.50 million for the quarter ended December 2009.

For the Consolidated period for the three month period ended December 2010, Aurobindo Pharma registered a net profit of Rs 1886.30 million for the perio under eview.

The total income of the company grew to Rs 11980.80 million for Oct-Dec period as against Rs 9252.50 million for the quarter ended December 2009.

In addition, the company has bagged tentative nod for the manufacture and sale of Famciclovir tabs from the USFDA.

The company bagged sanction to make and sell the tablets in the versions of 125mg, 250mg and 500mg.